目次

Table of Contents

Executive Summary
Market Overview

Market Landscape
Market ecosystem
Value chain analysis

Market Sizing
Market definition
Market segment analysis
Market size 2020
Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

Market Segmentation by Drug class
Market segments
Comparison by Drug class
Second-generation antipsychotic drugs - Market size and forecast 2020-2025
Third-generation antipsychotic drugs - Market size and forecast 2020-2025
First-generation antipsychotic drugs - Market size and forecast 2020-2025
Market opportunity by Drug class

Customer landscape

Geographic Landscape
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2020-2025
Europe - Market size and forecast 2020-2025
Asia - Market size and forecast 2020-2025
ROW - Market size and forecast 2020-2025
Key leading countries
Market opportunity By Geographical Landscape
Market drivers
Market challenges
Market trends

Vendor Landscape
Vendor landscape
Landscape disruption

Vendor Analysis
Vendors covered
Market positioning of vendors
AbbVie Inc.
Alkem Laboratories Ltd.
Alkermes Plc
AstraZeneca Plc
Biogen Inc.
Boehringer Ingelheim International GmbH
Dr. Reddys Laboratories Ltd.
Eli Lilly and Co.
Johnson and Johnson Inc.
Otsuka Holdings Co. Ltd.

Appendix
Scope of the report
Currency conversion rates for US$
Research methodology
List of abbreviations

1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2020 - 2025 ($ million)
13: Global market: Year-over-year growth 2020 - 2025 (%)
14: Five forces analysis 2020 & 2025
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2020
21: Drug class - Market share 2020-2025 (%)
22: Comparison by Drug class
23: Second-generation antipsychotic drugs - Market size and forecast 2020-2025 ($ million)
24: Second-generation antipsychotic drugs - Year-over-year growth 2020-2025 (%)
25: Third-generation antipsychotic drugs - Market size and forecast 2020-2025 ($ million)
26: Third-generation antipsychotic drugs - Year-over-year growth 2020-2025 (%)
27: First-generation antipsychotic drugs - Market size and forecast 2020-2025 ($ million)
28: First-generation antipsychotic drugs - Year-over-year growth 2020-2025 (%)
29: Market opportunity by Drug class
30: Customer landscape
31: Market share By Geographical Landscape 2020-2025 (%)
32: Geographic comparison
33: North America - Market size and forecast 2020-2025 ($ million)
34: North America - Year-over-year growth 2020-2025 (%)
35: Europe - Market size and forecast 2020-2025 ($ million)
36: Europe - Year-over-year growth 2020-2025 (%)
37: Asia - Market size and forecast 2020-2025 ($ million)
38: Asia - Year-over-year growth 2020-2025 (%)
39: ROW - Market size and forecast 2020-2025 ($ million)
40: ROW - Year-over-year growth 2020-2025 (%)
41: Key leading countries
42: Market opportunity By Geographical Landscape ($ million)
43: Impact of drivers and challenges
44: Vendor landscape
45: Landscape disruption
46: Industry risks
47: Vendors covered
48: Market positioning of vendors
49: AbbVie Inc. - Overview
50: AbbVie Inc. - Product and service
51: AbbVie Inc. - Key offerings
52: AbbVie Inc. - Key customers
53: AbbVie Inc. - Segment focus
54: Alkem Laboratories Ltd. - Overview
55: Alkem Laboratories Ltd. - Product and service
56: Alkem Laboratories Ltd. - Key offerings
57: Alkem Laboratories Ltd. - Key customers
58: Alkem Laboratories Ltd. - Segment focus
59: Alkermes Plc - Overview
60: Alkermes Plc - Business segments
61: Alkermes Plc - Key offerings
62: Alkermes Plc - Key customers
63: Alkermes Plc - Segment focus
64: AstraZeneca Plc - Overview
65: AstraZeneca Plc - Product and service
66: AstraZeneca Plc - Key offerings
67: AstraZeneca Plc - Key customers
68: AstraZeneca Plc - Segment focus
69: Biogen Inc. - Overview
70: Biogen Inc. - Business segments
71: Biogen Inc. - Key offerings
72: Biogen Inc. - Key customers
73: Biogen Inc. - Segment focus
74: Boehringer Ingelheim International GmbH - Overview
75: Boehringer Ingelheim International GmbH - Business segments
76: Boehringer Ingelheim International GmbH - Key offerings
77: Boehringer Ingelheim International GmbH - Key customers
78: Boehringer Ingelheim International GmbH - Segment focus
79: Dr. Reddys Laboratories Ltd. - Overview
80: Dr. Reddys Laboratories Ltd. - Business segments
81: Dr. Reddys Laboratories Ltd. - Key offerings
82: Dr. Reddys Laboratories Ltd. - Key customers
83: Dr. Reddys Laboratories Ltd. - Segment focus
84: Eli Lilly and Co. - Overview
85: Eli Lilly and Co. - Business segments
86: Eli Lilly and Co. - Key offerings
87: Eli Lilly and Co. - Key customers
88: Eli Lilly and Co. - Segment focus
89: Johnson and Johnson Inc. - Overview
90: Johnson and Johnson Inc. - Business segments
91: Johnson and Johnson Inc. - Key offerings
92: Johnson and Johnson Inc. - Key customers
93: Johnson and Johnson Inc. - Segment focus
94: Otsuka Holdings Co. Ltd. - Overview
95: Otsuka Holdings Co. Ltd. - Business segments
96: Otsuka Holdings Co. Ltd. - Key offerings
97: Otsuka Holdings Co. Ltd. - Key customers
98: Otsuka Holdings Co. Ltd. - Segment focus
99: Currency conversion rates for US$
100: Research Methodology
101: Validation techniques employed for market sizing
102: Information sources
103: List of abbreviations